Correction to: Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

被引：0
|
作者：
Fabian Sierra Morales
Igor J. Koralnik
Shiva Gautam
Soleil Samaan
Jacob A. Sloane
机构：
[1] Harvard Medical School,Division of Neuro
[2] Harvard Medical School,Immunology, Department of Neurology, Beth Israel Deaconess Medical Center, Multiple Sclerosis Center
[3] Harvard Medical School,Division of Biostatistics, Department of Medicine, Beth Israel Deaconess Medical Center
来源：
Journal of Neurology | 2020年 / 267卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Unfortunately, the given name and family name of first author was incorrectly tagged in the xml data, therefore it is abbreviated wrongly as “Morales FS” in Pubmed. The correct given name is Fabian and family name is Sierra Morales. Auhtor name should be abbreviated as Sierra Morales F.
引用
收藏
页码：132 / 132
相关论文
共 50 条
  • [21] Lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate: A single-center experience
    Dinoto, Alessandro
    Sartori, Arianna
    Cheli, Marta
    Pasquin, Fulvio
    Baldini, Sara
    Bratina, Alessio
    Bosco, Antonio
    Manganotti, Paolo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [22] Assessment of lymphopenia in patients with multiple sclerosis treated with dimethyl fumarate in a real clinical setting
    Alroughani, Raed
    Ahmed, Samar
    Behbehani, Raed
    Al-hashel, Jasem
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP18 - NP18
  • [23] Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
    Sangurdekar, Dipen
    Sun, Chao
    McLaughlin, Helen
    Ayling-Rouse, Katherine
    Allaire, Normand E.
    Penny, Michelle A.
    Bronson, Paola G.
    FRONTIERS IN GENETICS, 2019, 10
  • [24] Real world experience with dimethyl fumarate in relapsing-remitting multiple sclerosis
    Cox, S. R.
    Jordan, S.
    Sharma, D.
    O'Boyle, G.
    Tubridy, N.
    Hutchinson, M.
    Mcguigan, C.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 614 - 615
  • [25] Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis
    Sattarnezhad, Neda
    Healy, Brian C.
    Baharnoori, Moogeh
    Diaz-Cruz, Camilo
    Stankiewicz, James
    Weiner, Howard L.
    Chitnis, Tanuja
    NEUROLOGY, 2017, 88
  • [26] Dimethyl fumarate: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    Burness C.B.
    Deeks E.D.
    Drugs & Therapy Perspectives, 2014, 30 (9) : 303 - 308
  • [27] Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Haenni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Oezguer
    JOURNAL OF NEUROLOGY, 2021, 268 (03) : 941 - 949
  • [28] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [29] EXTENDING THERAPEUTIC POSSIBILITIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: DIMETHYL FUMARATE
    Matolcsi Judit
    Rozsa Csilla
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2015, 68 (1-2): : 7 - 14
  • [30] Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis
    Saijo, Naoya
    Abe, Yu
    Oikawa, Yoshitsugu
    Okubo, Yukimune
    Endo, Wakaba
    Numata-Uematsu, Yurika
    Takahashi, Toshiyuki
    Uematsu, Mitsugu
    BRAIN & DEVELOPMENT, 2022, 44 (05): : 353 - 356
12345